Vanguard Personalized Indexing Management
CBIO

Vanguard Personalized Indexing Management’s Crescent Biopharma CBIO Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-169
Closed -$3.56K – 1981
2025
Q1 		$3.56K Sell
169
-94
-36% -$2.52K ﹤0.01% 1839
2024
Q4 		$6.55K Buy
+263
New +$7.17K ﹤0.01% 1805

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Personalized Indexing Management's CBIO Position: Q2 2025 in Review

Vanguard Personalized Indexing Management sold out of Crescent Biopharma (CBIO) in Q2 2025, closing a stake of 169 shares — an estimated $3.56K sold.

Vanguard Personalized Indexing Management first reported a position in CBIO in Q4 2024 and held it in 2 quarters. The position peaked at $6.55K in Q4 2024. 30 funds tracked by Wall St. Rank hold CBIO as of Q2 2025.

  • Vanguard Personalized Indexing Management reported no remaining Crescent Biopharma position as of Q2 2025 after selling out during the quarter.
  • Vanguard Personalized Indexing Management sold 169 Crescent Biopharma shares in Q2 2025, an estimated $3.56K.
  • Vanguard Personalized Indexing Management first reported a position in Crescent Biopharma in Q4 2024 and held it in 2 quarters.
  • Vanguard Personalized Indexing Management's Crescent Biopharma position peaked at $6.55K in Q4 2024.
  • 30 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2025.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2025, filed 25 Jul 2025.